Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST, Amphadase, Cortrosyn, REXTOVYRANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at . This webcast will be available for 30 days following the presentation.
加州蘭喬庫卡蒙加 / ACCESSWIRE / 2024年11月13日 / amphastar pharmaceuticals公司（納斯達克：AMPH）今天宣佈，首席財務官Bill Peters和企業管理執行副總裁Jacob Liawatidewi將於2024年11月20日星期三下午3:30 GMT參加在傑弗里斯倫敦醫療會議上的分析師主持的閒聊。欲獲取訪問，請訪問amphastar的藥品網站。此網絡廣播將在演示後30天內可用。
About Amphastar:
關於Amphastar：
Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at .
Amphastar是一家以開發、製造、推廣和銷售技術上具有挑戰性的普通和專有注射、吸入和鼻內產品爲主的生物製藥公司。此外，該公司還銷售胰島素原料藥產品。該公司的大部分成品用於醫院或緊急護理臨床設置，並主要通過集團採購組織和藥品批發商進行承包和分銷。更多信息可在公司的網站上找到。
The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST, Amphadase, Cortrosyn, REXTOVY and BAQSIMI are the property of Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals的標誌和其他商標或服務標誌，包括但不限於Primatene Mist，Amphadase，Cortrosyn，REXTOVY和BAQSIMI均爲Amphastar Pharmaceuticals, Inc.的財產。
Forward Looking Statements
前瞻性聲明
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI, including its potential for continued revenue growth, the success of our integration of BAQSIMI, the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST or that we will continue to experience significant sales of BAQSIMI. You can locate these reports through our website at and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
本新聞稿和上述電話會議中的所有聲明，若非歷史性，都是前瞻性聲明，包括但不限於我們對未來財務表現和業務趨勢的期望、未來增長、產品銷售和營銷，市場規模和擴張，產品組合，產品研發，FDA對ANP DMF的申報或審批的時間，產品推出的時間，收購及與我們產品候選品管道相關的其他事項，臨床試驗的時間和結果，收購BAQSIMI的好處，包括潛在的持續營業收入增長，我們整合BAQSIMI的成功，我們向品牌產品、專利產品和生物類似物轉型的時間，我們利用現有專業知識和技術的能力以及其他未來事件。這些聲明不是事實，而是基於Amphastar的歷史表現以及我們對業務，運營和其他類似或相關因素的當前期望，估計和投影。我們使用"可能"，"可能"，"將"，"可能"，"將"，"應該"，"預期"，"預測"，"潛力"，"繼續"，"期望"，"打算"，"計劃"，"項目"，"相信"，"估計"和其他類似的表達來識別這些前瞻性聲明，儘管並非所有前瞻性聲明都包含這些詞語。您不應過分依賴前瞻性聲明，因爲它們涉及已知和未知的難以預測和在某些情況下超出Amphastar控制的風險，不確定性和假設。實際結果可能因一系列因素而與前瞻性聲明中的結果有所不同，這些因素在Amphastar向美國證券交易委員會提交的文件中進行了描述，包括我們在2023年12月31日結束的年度10-k表格中，於2024年2月29日向SEC提交，截至2024年3月31日的季度10-Q表格，於2024年5月10日向SEC提交，截至2024年6月30日的季度10-Q表格，於2024年8月9日向SEC提交。特別地，我們向高價值和高增長領域市場的轉變將取得成功，需求是否足夠來達到我們對Primatene MISt銷售目標的要求，或者我們是否會繼續大量銷售BAQSIMI，並無法保證。您可以通過我們的網站找到這些報告，以及美國證券交易委員會的網站www.sec.gov。本新聞稿中的前瞻性聲明僅於發佈日期發表。Amphastar不承擔就未來發生的事件或情況修改或更新本新聞稿或上述電話會議中的信息或任何前瞻性聲明的責任，即使有新信息可用或隨後發生的事件導致我們的期望改變。
Contact:
聯繫方式：
Bill Peters
Chief Financial Officer
(909) 476-3416
Bill Peters
首席財務官
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
信息來源：Amphastar Pharmaceuticals, Inc。
譯文內容由第三人軟體翻譯。
